Retatrutide triple agonist significantly cuts HbA1c by up to 1.94% in people with type 2 diabetes inadequately controlled by diet and exercise.

Type 2 diabetes (T2D) remains a global health challenge, often progressing despite lifestyle interventions. Current pharmacotherapies frequently fall short in achieving optimal glycemic control and addressing associated comorbidities like obesity. There's a critical need for novel agents that offer more comprehensive metabolic benefits. Retatrutide, a unique triple agonist targeting the GIP, GLP-1, and glucagon receptors, represents a promising approach to enhance insulin secretion, suppress glucagon, improve satiety, and potentially increase energy expenditure, offering a multi-faceted strategy for T2D management.

This 40-week, phase 3, randomized, double-blind, placebo-controlled trial enrolled 537 adults (mean age 48.8 years) across 48 sites. Participants had type 2 diabetes inadequately controlled by diet and exercise, with HbA1c between 7.0% and 9.5% and BMI ≥23 kg/m2. They were randomized (1:1:1:1) to once-weekly subcutaneous (SC) injections of Retatrutide 4 mg, 9 mg, 12 mg, or placebo. The primary endpoint was the change in HbA1c concentration from baseline to week 40.

Baseline mean HbA1c was 7.9% and mean BMI was 35.8 kg/m2. A total of 91% of participants completed the treatment period. For the treatment regimen estimand, mean HbA1c reductions from baseline were substantial across all Retatrutide doses: -1.69% with Retatrutide 4 mg, -1.86% with 9 mg, and -1.94% with 12 mg, compared to -0.81% with placebo.

The estimated treatment difference versus placebo for HbA1c reduction was -1.12% for Retatrutide 12 mg, -1.04% (95% CI -1.32 to -0.76) for 9 mg, and -0.88% (95% CI -1.18 to -0.59) for 4 mg. These results demonstrate dose-dependent and statistically significant improvements in glycemic control.